APPLICATION
ANDA090354
TYPE
ANDA
ORIGINAL APPROVAL
2009-12-28
LATEST ACTION
2024-05-01
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 250MG BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN SODIUMPrescription
AMPICILLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2024-05-01Labeling · Supplement 7 · standardAP
2018-03-23Labeling · Supplement 4 · standardAP
2018-03-23Labeling · Supplement 5 · standardAP
2009-12-28OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.